Advice

in the absence of a submission from the holder of the marketing authorisation:

doravirine / lamivudine / tenofovir disoproxil (Delstrigo) is not recommended for use within NHSScotland.

Indication under review: Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice357KB (PDF)

Download

Medicine details

Medicine name:
doravirine/lamivudine/tenofovir disoproxil (Delstrigo)
SMC ID:
SMC2163
Indication:
Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
11 February 2019